+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
FEMALE
ID03564340

Study of Ubamatamab Alone or With Cemiplimab in Adult Women With Recurrent Ovarian or MUC16-Positive Uterine Cancers

Led by Regeneron Pharmaceuticals · Updated on 2026-09-25

890

Participants Needed

54

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and dosing of ubamatamab alone or combined with cemiplimab in adult women with recurrent ovarian or uterine cancers that express MUC16. The study aims to understand how these drugs behave in the body, their potential to treat advanced recurrent ovarian or uterine cancer, and how pretreatment might help prevent Cytokine Release Syndrome CRS. This trial is a Phase 12 treatment study sponsored by Regeneron Pharmaceuticals. Participants receive ubamatamab alone or together with cemiplimab according to the study protocol. The trial evaluates different doses and combinations to find the best regimen. The study also includes pretreatment to assess its safety and effectiveness in reducing CRS. Treatments are given sequentially in two experimental groups monotherapy with ubamatamab and combination therapy with ubamatamab plus cemiplimab. During the study, participants undergo safety monitoring for dose-limiting toxicities, treatment-related adverse events, and serious events up to 2 years. Researchers measure drug levels in the blood and assess tumor responses using established cancer response criteria. Quality of life, physical function, and symptom scores are also tracked over time. The study collects data on immune response and long-term outcomes, with regular assessments throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here